scholarly journals Objective Assessment of Impulse Control Disorder in Patients with Parkinson’s Disease Using a Low-Cost LEGO-Like EEG Headset

Author(s):  
Yuan-Pin Lin ◽  
Hsing-Yi Liang ◽  
Yueh-Sheng Chen ◽  
Cheng-Hsien Lu ◽  
Yih-Ru Wu ◽  
...  

Abstract BackgroundPatients with Parkinson’s disease (PD) can develop the cognitive adverse effect of impulse control disorders (ICDs) while undergoing a pharmacological treatment for motor control dysfunctions with a dopamine agonist (DA). Conventional clinical interviews or questionnaires can be biased and may not provide an accurate diagnosis in the early stage. A wearable electroencephalogram (EEG)-sensing headset paired with an examination procedure can be a potential user-friendly method to explore ICD-related biomarkers that can reflect brain activity abnormalities and detect its early signs and progression.MethodsA stereotypical Go/NoGo test that targets impulse inhibition was performed with 59 individuals, including heathy controls, patients with PD, and patients with PD diagnosed with ICD. A low-cost LEGO-like EEG headset was used to record concurrent EEG signals. The event-related potential (ERP) analytical framework was then used to explore ICD-related EEG abnormalities after DA treatment.ResultsOnly PD patients with ICD exhibited a tendency for N2 and P3 amplitude deterioration at the fronto-central regions (i.e., Fz, FCz, and Cz); in particular, the P3 counterpart reached statistical significance (p<0.05). Neither PD patients nor healthy controls (without DA) replicated such findings. Furthermore, N2 amplitude deterioration was found to be related to ICD severity at Fz (r=-0.28, p=0.04).ConclusionsA low-cost LEGO-like EEG headset successfully captured ERP neuromarkers for the objective assessment of ICD in PD patients undergoing DA treatment. The present objective neuro-evidence could provide complementary information to conventional clinical scales used to diagnose the ICD adverse effect.

2013 ◽  
Vol 7 (4) ◽  
pp. 351-359 ◽  
Author(s):  
Chun-Xiao Han ◽  
Jiang Wang ◽  
Guo-Sheng Yi ◽  
Yan-Qiu Che

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Beatriz Muñoz Ospina ◽  
Jaime Andrés Valderrama Chaparro ◽  
Juan David Arango Paredes ◽  
Yor Jaggy Castaño Pino ◽  
Andrés Navarro ◽  
...  

Background. Gait alterations are hallmarks for the diagnosis and follow-up of patients with Parkinson’s disease (PD). In normal conditions, age could affect gait dynamics. Although it is known that objective assessment of gait is a valuable tool for diagnosis and follow-up of patients with PD, only few studies evaluate the effect of aging on the gait pattern of patients with PD. Objective. The purpose of this study was to assess differences in gait dynamics between PD patients and healthy subjects and to investigate the effects of aging on these differences using a low-cost RGB-D depth-sensing camera. Methods. 30 PD patients and 30 age-matched controls were recruited. Descriptive analysis was used for clinical variables, and Spearman’s rank correlation was used to correlate age and gait variables. The sample was distributed in age groups; then, Mann–Whitney U test was used for comparison of gait variables between groups. Results. PD patients exhibited prolonged swing (p=0.002) and stance times (p<0.001) and lower speed values (p<0.001) compared to controls. This was consistent in all age groups, except for the one between 76 and 88 years old, in which the controls were slower and had longer swing and stance times. These results were statically significant for the group from 60 to 66 years. Conclusion. Gait speed, swing, and stance times are useful for differentiating PD patients from controls. Quantitative gait parameters measured by an RGB-D camera can complement clinical assessment of PD patients. The analysis of these spatiotemporal variables should consider the age of the subject.


2020 ◽  
Vol 10 (4) ◽  
pp. 1541-1549
Author(s):  
Seok Jong Chung ◽  
Sangwon Lee ◽  
Han Soo Yoo ◽  
Yang Hyun Lee ◽  
Hye Sun Lee ◽  
...  

Background: Striatal dopamine deficits play a key role in the pathogenesis of Parkinson’s disease (PD), and several non-motor symptoms (NMSs) have a dopaminergic component. Objective: To investigate the association between early NMS burden and the patterns of striatal dopamine depletion in patients with de novo PD. Methods: We consecutively recruited 255 patients with drug-naïve early-stage PD who underwent 18F-FP-CIT PET scans. The NMS burden of each patient was assessed using the NMS Questionnaire (NMSQuest), and patients were divided into the mild NMS burden (PDNMS-mild) (NMSQuest score <6; n = 91) and severe NMS burden groups (PDNMS-severe) (NMSQuest score >9; n = 90). We compared the striatal dopamine transporter (DAT) activity between the groups. Results: Patients in the PDNMS-severe group had more severe parkinsonian motor signs than those in the PDNMS-mild group, despite comparable DAT activity in the posterior putamen. DAT activity was more severely depleted in the PDNMS-severe group in the caudate and anterior putamen compared to that in the PDMNS-mild group. The inter-sub-regional ratio of the associative/limbic striatum to the sensorimotor striatum was lower in the PDNMS-severe group, although this value itself lacked fair accuracy for distinguishing between the patients with different NMS burdens. Conclusion: This study demonstrated that PD patients with severe NMS burden exhibited severe motor deficits and relatively diffuse dopamine depletion throughout the striatum. These findings suggest that the level of NMS burden could be associated with distinct patterns of striatal dopamine depletion, which could possibly indicate the overall pathological burden in PD.


Author(s):  
М.М. Руденок ◽  
А.Х. Алиева ◽  
А.А. Колачева ◽  
М.В. Угрюмов ◽  
П.А. Сломинский ◽  
...  

Несмотря на очевидный прогресс, достигнутый в изучении молекулярно-генетических факторов и механизмов патогенеза болезни Паркинсона (БП), в настоящее время стало ясно, что нарушения в структуре ДНК не описывают весь спектр патологических изменений, наблюдаемых при развитии заболевания. В настоящее время показано, что существенное влияние на патогенез БП могут оказывать изменения на уровне транскриптома. В работе были использованы мышиные модели досимптомной стадии БП, поздней досимптомной и ранней симптомной (РСС) стадиями БП. Для полнотранскриптомного анализа пулов РНК тканей черной субстанции и стриатума мозга мышей использовались микрочипы MouseRef-8 v2.0 Expression BeadChip Kit («Illumina», США). Полученные данные указывают на последовательное вовлечение транскриптома в патогенез БП, а также на то, что изменения на транскриптомном уровне процессов транспорта и митохондриального биогенеза могут играть важную роль в нейродегенерации при БП уже на самых ранних этапах. Parkinson’s disease (PD) is a complex systemic disease, mainly associated with the death of dopaminergic neurons. Despite the obvious progress made in the study of molecular genetic factors and mechanisms of PD pathogenesis, it has now become clear that violations in the DNA structure do not describe the entire spectrum of pathological changes observed during the development of the disease. It has now been shown that changes at the transcriptome level can have a significant effect on the pathogenesis of PD. The authors used models of the presymptomatic stage of PD with mice decapitation after 6 hours (6 h-PSS), presymptomatic stage with decapitation after 24 hours (24 h-PSS), advanced presymptomatic (Adv-PSS) and early symptomatic (ESS) stages of PD. For whole transcriptome analysis of RNA pools of the substantia nigra and mouse striatum, the MouseRef-8 v2.0 Expression BeadChip Kit microchips (Illumina, USA) were used. As a result of the analysis of whole transcriptome data, it was shown that, there are a greater number of statistically significant changes in the tissues of the brain and peripheral blood of mice with Adv-PSS and ESS models of PD compared to 6 h-PSS and 24 h-PSS models. In general, the obtained data indicate the sequential involvement of the transcriptome in the pathogenesis of PD, as well as the fact that changes at the transcriptome level of the processes of transport and mitochondrial biogenesis can play an important role in neurodegeneration in PD at an early stage.


Sign in / Sign up

Export Citation Format

Share Document